The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.
Immune responses mediated by IgE are important in the pathogenesis of allergic asthma. A recombinant humanized monoclonal antibody (rhuMAb-E25) forms complexes with free IgE and blocks its interaction with mast cells and basophils. We studied the efficacy of rhuMab-E25 as a treatment for moderate-to-severe allergic asthma. ⋯ A recombinant humanized monoclonal antibody directed against IgE has potential as a treatment for subjects with moderate or severe allergic asthma.